EDSA
Edesa Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$4.90
+2.84%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 102.8K | 119.3K | — | — | — |
| Gross Profit | (102.8K) | (119.3K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 9.1M | 3.7M | 2.9M | 4.8M | 13.3M |
| SG&A Expense | 5.6M | 4.2M | 4.1M | 4.4M | 5.0M |
| General & Admin Expense | 5.6M | 4.2M | 4.1M | 4.4M | 5.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (77.2K) | (119.3K) | — | — | — |
| Total Operating Expenses | 14.6M | 7.8M | 7.0M | 9.2M | 18.4M |
| Cost and Expenses | 14.6M | 7.9M | 7.0M | 9.2M | 18.4M |
| Operating Income (EBIT) | (14.6M) | (7.9M) | (7.0M) | (9.2M) | (18.4M) |
| Non-Operating | |||||
| Interest Income | 1.0K | 2.6K | 153.5K | 289.8K | 63.5K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 1.0K | 2.6K | 153.5K | 289.8K | 63.5K |
| Other Non-Op Income/Expense | 527.0K | 726.8K | 845.5K | 849.1K | 822.7K |
| Non-Operating Income (excl Interest) | (247.2K) | (726.8K) | (698.3K) | (581.0K) | (780.3K) |
| EBT (Pre-Tax Income) | (14.1M) | (7.2M) | (6.2M) | (8.4M) | (17.5M) |
| Income Tax Expense | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 |
| Bottom Line | |||||
| Net Income | (14.1M) | (7.2M) | (6.2M) | (8.4M) | (17.5M) |
| Earnings from Cont. Ops | (14.1M) | (7.2M) | (6.2M) | (8.4M) | (17.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (14.1M) | (7.2M) | (6.2M) | (8.4M) | (17.5M) |
| Per Share | |||||
| Basic EPS | ($1.69) | ($1.27) | ($1.93) | ($2.93) | ($8.37) |
| Diluted EPS | ($1.69) | ($1.27) | ($1.93) | ($2.93) | ($8.37) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 9.0M | 5.7M | 3.2M | 2.9M | 2.1M |
| Diluted Shares Outstanding | 9.0M | 5.7M | 3.2M | 2.9M | 2.1M |
| Profitability Metrics | |||||
| EBITDA | (14.3M) | (7.1M) | (6.1M) | (8.5M) | (17.5M) |
| D&A | 102.8K | 119.3K | 186.0K | 183.5K | 118.2K |
| EBIT | (14.4M) | (7.2M) | (6.3M) | (8.6M) | (17.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026